Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:32:42.780Z.
Calculation as of: 2026-10-06T16:32:42.780Z.
Quote observation: 2026-10-06T16:30:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80f889fb03c5e90f23e6dbb960addb407f240d79d9565bd54dedfb6815f2f0ce
PE RATIO
N/A
Market Cap
$4.39B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.42B
PE Ratio
12.69
TTM Avg
20.82
3Y Avg
83.80
5Y Avg
77.36
Market Cap
$4.12B
PE Ratio
N/A
TTM Avg
15.33
3Y Avg
3382.02
5Y Avg
3382.02
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.44B | N/A | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.32B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 12.69 | 20.82 | 83.80 | 77.36 |
| BillionToOne, Inc. (BLLN)vs › | $4.56B | 160.04 | 879.32 | 879.32 | 879.32 |
| LivaNova PLC (LIVN)vs › | $4.15B | 22.29 | 33.07 | 280.21 | 280.21 |
| AbCellera Biologics Inc. (ABCL)vs › | $4.12B | N/A | 15.33 | 3382.02 | 3382.02 |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.09B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 23.36 | 21.05 | 22.44 | 28.91 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 93.22 | 202.48 | 202.48 | 202.48 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$51.44
Forward EPS (Est.)
$-0.41
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
